NL-OMON48876
Recruiting
Phase 2
Allogeneic bone marrow derived mesenchymal stromal cells for the treatment of refractory proctitis in Ulcerative Colitis - BMMSC proctitis
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Ulcerative Colitis
- Sponsor
- eids Universitair Medisch Centrum
- Enrollment
- 14
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •a) Men and women \>\= 18 years of age;
- •b) Patient must have ulcerative colitis confirmed by endoscopic and histologic evidence;
- •c) Inflammation must be limited to the rectum (up to 15 cm beyond the anal verge), confirmed by endoscopy maximum 3 months before baseline (slight inflammation in other parts of the colon is accepted with a maximum Mayo Score of 1\);
- •d) Moderate to severe proctitis indicated by a Mayo Score of 2 or 3;
- •e) Proctitis must be refractory to conventional medical therapy. Which means that at some time during the course of the disease, patient must have received rectal 5\-ASA therapy and rectal corticosteroid therapy for at least 4 weeks which did not result in an adequate response to treatment;
- •f) If treated with rectal therapy, therapy must be stopped two weeks before endoscopic implantation of MSCs and only restarted after 6 weeks;
- •g) If treated with oral 5\-ASA therapy, dose must be stable for 4 weeks prior to study entry and remain on same dose during the first 6 weeks after MSC treatment;
- •h) If treated with oral corticosteroids, dose must be stable for 2 weeks prior to study entry and remain on same dose during the first 6 weeks after MSC treatment;
- •i) If treated with 6\-mercaptopurine, methotrexate, azathioprine, vedolizumab or anti\-TNF therapy patients must have been on medication for 3 months and a stable dose for 2 months prior to study entry and remain on same dose during the first 6 weeks after MSC treatment;
- •j) If female and of child\-bearing age, patient must be non\-pregnant, non\-breastfeeding, and use adequate contraception;
Exclusion Criteria
- •a) Patients suffering from renal\- or hepatic failure;
- •b) Use of any investigational drug within 1 month prior to screening or within 5 half\-lives of the investigational agent, whichever is longer;
- •c) Positive stool culture for enteric pathogens (salmonella, shigella, and campylobacter), positive C. difficile toxin, or positive stool ova and parasite exam;
- •d) All active infections requiring treatment;
- •e) Patients who had tuberculosis or an opportunistic infection (e.g., herpes zoster \[shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis) within 6 months prior to screening;
- •f) Malignancy within the past 5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence);
- •g) Any dysplasia in the colon in the past 5 years, except for a successfully removed sporadic adenoma;
- •h) Very severe proctitis; expected to result in hospitalization/ surgery within 3 months;
- •i) Previous treatment with allogeneic MSCs;
- •j) Any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the study;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Mesenchymal Stromal Cells for the treatment of Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2017-003524-75-NLeiden University Medical Center14
Not yet recruiting
Not Applicable
Mesenchymal stromal cell therapy for the treatment of proctitis in ulcerative colitisNL-OMON21802eiden University Medical Center14
Completed
Not Applicable
Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients with Refractory Perianal Crohn*s DiseasefistulaM. Crohn10017969NL-OMON36386eids Universitair Medisch Centrum21
Active, not recruiting
Not Applicable
Allogeneic Bone Marrow Derived Mesenchymal Stem Cellsfor the Treatment of Fistulas in Patients withRefractory Perianal Crohn’s Disease - allo bmMSCs CD fistulaEUCTR2009-015680-14-NLeiden University Medical Center
Active, not recruiting
Phase 1
Safety of bone marrow-derived stem cells in treatment of knee cartilage defects.EUCTR2018-004067-31-CZBioinova, s.r.o.6